Monitor upcoming IND filings for CBP (FHT-171) and EP300 degraders in 2027 and Phase 1 efficacy data for FHD-909 as key catalysts. Cash runway into H1 2028 reduces near-term dilution risk.
Price Chart
Executive Summary
Foghorn Therapeutics reported Q1 2026 collaboration revenue of $3.3M (down from $6.0M YoY), net loss of $19.9M (vs $18.8M), and EPS of -$0.29 (vs consensus -$0.28, a slight miss). Cash stood at $183.6M, extended into H1 2028. Pipeline advances remain on track, with Phase 1 FHD-909 trial progressing and selective CBP/EP300 degraders approaching IND-enabling studies.
Key Financial Metrics
Key Facts
- Collaboration revenue $3.3M for Q1 2026, down from $6.0M YoY due to timing of work under Lilly agreement
- Net loss $19.9M vs $18.8M YoY; EPS -$0.29 vs -$0.30 YoY
- Cash, cash equivalents and marketable securities $183.6M as of March 31, 2026, providing runway into H1 2028
- FHD-909 Phase 1 dose-escalation trial on track; IND-enabling studies for CBP and EP300 degraders expected in 2026 with INDs in 2027
- Selected preclinical data presented at AACR 2026 showing combination activity with anti-PD-1 and KRAS inhibitors
Financial Impact
No material financial impact; company remains pre-revenue with collaboration revenue variability
Risk Factors
- Clinical trial delays or failures, particularly for FHD-909
- Dependence on Lilly collaboration for revenue and development
- Need for additional capital beyond 2028 runway
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-031669 |
| Document: a2026mayfoghornirpresent.htm | 0001628280-26-031669 |
| Document: fhtx-20260507.htm | 0001628280-26-031669 |
| Document: 0001628280-26-031669-index-headers.html | 0001628280-26-031669 |
| Document: 0001628280-26-031669-index.html | 0001628280-26-031669 |
| Document: 0001628280-26-031669.txt | 0001628280-26-031669 |
| 8-K Data (Synthetic) | 0001628280-26-031669 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $5.57 $4.87 | ▼ −12.57% | ▼ −13.17% | $2.06 (−63.11%) |
May 7, 2026 21w ago | 8-K | $4.20 $3.64 | ▼ −13.33% | ▼ −16.47% | $2.06 (−51.07%) |
Apr 21, 2026 23w ago | Press Release | $5.39 $3.60 | ▼ −33.21% | ▼ −36.38% | $2.06 (−61.87%) |
Apr 21, 2026 23w ago | 8-K | $5.39 $3.60 | ▼ −33.21% | ▼ −36.38% | $2.06 (−61.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access